Literature DB >> 1623401

Interactions of fluoxetine with metabolism of dopamine and serotonin in rat brain regions.

R J Baldessarini1, E R Marsh, N S Kula.   

Abstract

Given evidence of inhibitory effects of serotonin on dopaminergic neurotransmission, a series of experiments sought neurochemical evidence of interactions between the selective serotonin transport inhibitor fluoxetine and the metabolism of dopamine (DA) or serotonin (5-HT) in regions of rat brain that might account for extrapyramidal side-effects associated with clinical use of fluoxetine. There were significant inhibitory effects of acute or repeated fluoxetine treatment on the turnover of 5-HT (accumulation of 5-hydroxytryptophan, or ratio of [5-hydroxyindoleacetic acid]/[5-HT]) in striatum, nucleus accumbens and frontal cerebral cortex, but only minor effects on metabolism of DA (accumulation of dihydroxyphenylalanine, or [homovanillic acid]/[DA] ratio), even at high doses or with repeated treatment, and no significant inhibition of the DA metabolism-increasing actions of haloperidol.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623401     DOI: 10.1016/0006-8993(92)90754-w

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

1.  Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa.

Authors:  D A M C van de Vijver; R A C Roos; P A F Jansen; A J Porsius; A de Boer
Journal:  Br J Clin Pharmacol       Date:  2002-08       Impact factor: 4.335

2.  Behavioral disturbance in dementia.

Authors:  Abhilash K Desai; Lori Schwartz; George T Grossberg
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

Review 3.  Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?

Authors:  Henry Silver; Yael Chertkow; Orly Weinreb; Lena Danovich; Moussa Youdim
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

4.  A case of needle fixation.

Authors:  Yvonne Treffurth; Hem Raj Pal
Journal:  BMJ Case Rep       Date:  2010-04-05

5.  Effects of acute or repeated paroxetine and fluoxetine treatment on affective behavior in male and female adolescent rats.

Authors:  Leslie R Amodeo; Venuz Y Greenfield; Danielle E Humphrey; Veronica Varela; Joseph A Pipkin; Shannon E Eaton; Jelesa D Johnson; Christopher P Plant; Zachary R Harmony; Li Wang; Cynthia A Crawford
Journal:  Psychopharmacology (Berl)       Date:  2015-07-05       Impact factor: 4.530

6.  The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ('ecstasy')-induced degeneration of 5-HT nerve endings in rat brain.

Authors:  V Sanchez; J Camarero; B Esteban; M J Peter; A R Green; M I Colado
Journal:  Br J Pharmacol       Date:  2001-09       Impact factor: 8.739

7.  Dopamine and serotonin metabolism in response to chronic administration of fluvoxamine and haloperidol combined treatment.

Authors:  Y Chertkow; O Weinreb; M B H Youdim; H Silver
Journal:  J Neural Transm (Vienna)       Date:  2007-06-18       Impact factor: 3.575

8.  Acute effects of combining citalopram and pindolol on regional brain serotonin synthesis in sham operated and olfactory bulbectomized rats.

Authors:  Khanh Q Nguyen; Yoshihiro Tohyama; Arata Watanabe; Shu Hasegawa; Ivan Skelin; Mirko Diksic
Journal:  Neurochem Int       Date:  2008-11-27       Impact factor: 3.921

9.  Differential effects of acute and chronic fluoxetine administration on the spontaneous activity of dopaminergic neurones in the ventral tegmental area.

Authors:  S Prisco; E Esposito
Journal:  Br J Pharmacol       Date:  1995-09       Impact factor: 8.739

10.  A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia.

Authors:  D C Goff; K K Midha; O Sarid-Segal; J W Hubbard; E Amico
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.